Pre-made Actinium (225Ac) Lintuzumab Satetraxetan benchmark antibody (Whole mAb ADC, anti-CD33 therapeutic antibody, Anti-SIGLEC-3/SIGLEC3/p67 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-INN-717

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-INN-717 Category Tag

Product Details

Pre-made Actinium (225Ac) Lintuzumab Satetraxetan benchmark antibody (Whole mAb ADC, anti-CD33 therapeutic antibody, Anti-SIGLEC-3/SIGLEC3/p67 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Products Name (INN Index)

Pre-Made Actinium (225Ac) Lintuzumab Satetraxetan Biosimilar, Whole Mab Adc, Anti-Cd33 Antibody: Anti-SIGLEC-3/SIGLEC3/p67 therapeutic antibody Drug Conjugate

INN Name

actinium (225Ac) lintuzumab satetraxetan

Target

CD33

Format

Whole mAb ADC

Derivation

Humanized

Species Reactivity

Human

CH1 Isotype

IgG1 – kappa

VD LC

IgG1 – kappa

Highest_Clin_Trial (Jan '20)

NA

Est. Status

NA

100% SI Structure

NA

99% SI Structure

NA

95-98% SI Structure

NA

Year Proposed

NA

Companies

Actinium Pharmaceuticals, Inc. (New York NY USA)

Conditions Approved

NA

Conditions Active

NA

Conditions Discontinued

NA

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

CD33

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide